Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2562971 | 0.86 | ALDH1A1 (0.55) | HPGDCYP1A2POLBRECQLHTT | |
| SCHEMBL31104526 | 0.83 | P2RX7 (0.56) | HPGDMAPTPOLBRECQLHTT | |
| SCHEMBL25284100 | 0.81 | TMEM97 (0.47) | HPGDMAPTGAAKMT2AALDH1A1 | |
| SCHEMBL7223858 | 0.79 | HPGD (0.68) | HPGDCYP1A2MAPTPOLBGAA | |
| SCHEMBL1645411 | 0.79 | MEN1 (0.58) | CYP1A2MAPTPOLBGAAHTT | |
| SCHEMBL20505282 | 0.77 | HPGD (0.49) | HPGDMAPTTSHRKMT2AALDH1A1 | |
| SCHEMBL22589603 | 0.77 | TSHR (0.49) | HPGDCYP1A2MAPTPOLBGAA | |
| SCHEMBL2566261 | 0.77 | HPGD (0.69) | HPGDCYP1A2MAPTPOLBGAA | |
| SCHEMBL1169501 | 0.76 | KMT2A (0.56) | HPGDCYP1A2MAPTPOLBGAA | |
| SCHEMBL29092068 | 0.76 | HPGD (0.66) | HPGDCYP1A2MAPTPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399416-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-1399416-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6852882-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040157916-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2004-08-12 | — | — | US | disclosed |
| EP-1399416-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002098901-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157916-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | HPGD 2537/4885CYP1A2 4681/4885MAPT 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.